|

S&P 500 Futures: Tests 3,500 after Pharmamar says Aplidin drug is enormously promising in treating COVID-19

With the global COVID-19 count topping 40 million, amid the latest surge in the European coronavirus cases, Spanish pharmaceutical company PharmaMar came out with a piece of welcome news, citing that its cancer drug - Aplidin is enormously promising in treating COVID-19.

This comes after the Spanish pharma giant said Friday, a clinical trial of its cancer drug Aplidin to treat adult patients with COVID-19 was successful and it now aims to start phase III trials.

The statement read: "With these data, the company will begin, in the next few days, conversations with the regulatory agencies to define the next phase III pivotal study for plitidepsin (Aplidin) in patients with COVID-19, who require hospitalization."

Note that the drug is approved in Australia for the treatment of multiple myeloma.

S&P 500 futures rebound to 3,500

Amid encouraging vaccine news and upbeat European earnings reports, the sentiment remains lifted and helps boost the recovery in the S&P 500 futures.

The futures tied to the S&P 500 index rallies 0.88% to trade at 3,493, recovering from Friday’s low of 3,461.25.

Author

Dhwani Mehta

Dhwani Mehta

FXStreet

Residing in Mumbai (India), Dhwani is a Senior Analyst and Manager of the Asian session at FXStreet. She has over 10 years of experience in analyzing and covering the global financial markets, with specialization in Forex and commodities markets.

More from Dhwani Mehta
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD clings to small gains near 1.1750

Following a short-lasting correction in the early European session, EUR/USD regains its traction and clings to moderate gains at around 1.1750 on Monday. Nevertheless, the pair's volatility remains low, with investors awaiting this weeks key data releases from the US and the ECB policy announcements.

GBP/USD edges higher toward 1.3400 ahead of US data and BoE

GBP/USD reverses its direction and advances toward 1.3400 following a drop to the 1.3350 area earlier in the day. The US Dollar struggles to gather recovery momentum as markets await Tuesday's Nonfarm Payrolls data, while the Pound Sterling holds steady ahead of the BoE policy announcements later in the week.

Gold stuck around $4,300 as markets turn cautious

Gold loses its bullish momentum and retreats below $4,350 after testing this level earlier on Monday. XAU/USD, however, stays in positive territory as the US Dollar remains on the back foot on growing expectations for a dovish Fed policy outlook next year.

Ethereum: BitMine acquires 102,259 ETH as price plunges 5%

Ethereum treasury company BitMine Immersion scaled up its digital asset stash last week after acquiring 102,259 ETH since its last update. The purchase has increased the company's holdings to 3.96 million ETH, worth about $11.82 billion. BitMine aims to accumulate 5% of ETH's circulating supply.

Big week ends with big doubts

The S&P 500 continued to push higher yesterday as the US 2-year yield wavered around the 3.50% mark following a Federal Reserve (Fed) rate cut earlier this week that was ultimately perceived as not that hawkish after all. The cut is especially boosting the non-tech pockets of the market.

Solana Price Forecast: SOL consolidates as spot ETF inflows near $1 billion signal institutional dip-buying

Solana (SOL) price hovers above $131 at the time of writing on Monday, nearing the upper boundary of a falling wedge pattern, awaiting a decisive breakout.